TY - JOUR
T1 - Association of ABCC2 polymorphisms with platinum-based chemotherapy response and severe toxicity in non-small cell lung cancer patients
AU - Han, Baohui
AU - Gao, Ge
AU - Wu, Wenting
AU - Gao, Zhiqiang
AU - Zhao, Xueying
AU - Li, Ling
AU - Qiao, Rong
AU - Chen, Hongyan
AU - Wei, Qingyi
AU - Wu, Jinchang
AU - Lu, Daru
N1 - Funding Information:
This work was supported in part by Shanghai Science and Technology Research Program ( 06DZ19501 , 09JC1402200 ), Natural Science Foundation of China ( 30800622 ) and Shanghai Subject Chief Scientist for Public Health 08GWD07 , Fudan University Key Disciplines Creative Talents Cultivation Program .
PY - 2011/5
Y1 - 2011/5
N2 - Platinum-based chemotherapy is the most common treatment for non-small cell lung cancer (NSCLC), and expression levels of drug metabolism and transport proteins are correlated with its efficacy and toxicity. In this study, we investigated the association of three putative functional polymorphisms of ABCC2 (C-24T, G1249A, and C3972T) with tumor response and occurrence of the grade 3 or 4 toxicity in 445 patients with stage III and IV NSCLC treated with platinum-based chemotherapy. We determined the genotypes of these three polymorphisms by the matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MassArray) method. We found that the common homozygotes of -24C was associated with a better treatment response (adjusted odds ratios [ORs], 1.84; 95% confidence interval [CI], 1.05-3.23; P= 0.032). Furthermore, patients with 3972T had increased risk of severe thrombocytopenia toxicity (adjusted OR, 2.43; 95% CI, 1.06-5.56; P= 0.034); and in female subgroup analyses, this variant was associated with significantly increased risk of overall toxicity (adjusted OR, 2.63; 95% CI, 1.17-5.95; P= 0.02), particularly of hematologic toxicity (adjusted OR, 3.80; 95% CI, 1.62-8.87; P= 0.002). Moreover, -24T/3972T haplotype was also associated with significantly increased risk of hematologic toxicity. Our results suggested that C-24T variants had an effect on treatment response and that C3972T had an effect on severe toxicities among platinum-treated non-small cell lung cancer patients.
AB - Platinum-based chemotherapy is the most common treatment for non-small cell lung cancer (NSCLC), and expression levels of drug metabolism and transport proteins are correlated with its efficacy and toxicity. In this study, we investigated the association of three putative functional polymorphisms of ABCC2 (C-24T, G1249A, and C3972T) with tumor response and occurrence of the grade 3 or 4 toxicity in 445 patients with stage III and IV NSCLC treated with platinum-based chemotherapy. We determined the genotypes of these three polymorphisms by the matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MassArray) method. We found that the common homozygotes of -24C was associated with a better treatment response (adjusted odds ratios [ORs], 1.84; 95% confidence interval [CI], 1.05-3.23; P= 0.032). Furthermore, patients with 3972T had increased risk of severe thrombocytopenia toxicity (adjusted OR, 2.43; 95% CI, 1.06-5.56; P= 0.034); and in female subgroup analyses, this variant was associated with significantly increased risk of overall toxicity (adjusted OR, 2.63; 95% CI, 1.17-5.95; P= 0.02), particularly of hematologic toxicity (adjusted OR, 3.80; 95% CI, 1.62-8.87; P= 0.002). Moreover, -24T/3972T haplotype was also associated with significantly increased risk of hematologic toxicity. Our results suggested that C-24T variants had an effect on treatment response and that C3972T had an effect on severe toxicities among platinum-treated non-small cell lung cancer patients.
KW - ABCC2
KW - Non-small cell lung cancer
KW - Platinum
KW - Polymorphisms
KW - Response
KW - Toxicity
UR - http://www.scopus.com/inward/record.url?scp=79953796265&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79953796265&partnerID=8YFLogxK
U2 - 10.1016/j.lungcan.2010.09.001
DO - 10.1016/j.lungcan.2010.09.001
M3 - Article
C2 - 20943283
AN - SCOPUS:79953796265
SN - 0169-5002
VL - 72
SP - 238
EP - 243
JO - Lung Cancer
JF - Lung Cancer
IS - 2
ER -